NCT01005875TerminatedNot Applicable
RAD 0901- Stereotactic Radiation Therapy and Sorafenib in the Treatment of Hepatocellular Carcinoma
University of Alabama at Birmingham1 site in 1 country5 target enrollmentStarted: November 2009Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Not Applicable
- Status
- Terminated
- Enrollment
- 5
- Locations
- 1
- Primary Endpoint
- Determine the Safety and Tolerability of Sequential SBRT and Sorafenib in Patients With Unresectable Hepatocellular Carcinoma
Study Overview
Brief Summary
This study is to determine the safety and efficacy of stereotactic body radiotherapy (SBRT) and treatment drug in patients with hepatocellular carcinoma.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 19 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Child-Pugh class A or B7 cirrhosis.
- •No prior radiation therapy to the upper right abdominal quadrant.
- •Size of each tumor less than 6 cm.
- •Three or less known lesions.
- •More than 800 cc of uninvolved liver.
- •Age > 19 years old
- •ECOG Performance Status 0 or 1
- •Adequate bone marrow, liver and renal function as assessed by the following:
- •Hemoglobin > 8.5 g/dl
- •Platelet count > 50,000/mm3
- •Total bilirubin < 1.5 times ULN
- •ALT and AST < 2.5 times the ULN ( < 5 x ULN for patients with liver involvement)
- •Creatinine < 1.5 times ULN
- •Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatment
- •Women of childbearing potential and men must agree to use adequate contraception (barrier method of birth control) prior to study entry and for the duration of study participation. Men should use adequate birth control for at least three months after the last administration of sorafenib.
- •Ability to understand and the willingness to sign a written informed consent. A signed informed consent must be obtained prior to any study specific procedures.
- •INR < 1.5 or a PT/PTT within normal limits. Patients receiving anti-coagulation treatment with an agent such as warfarin or heparin may be allowed to participate. For patients on warfarin, the INR should be measured prior to initiation of sorafenib and monitored at least weekly, or as defined by the local standard of care, until INR is stable.
Exclusion Criteria
- •Child-Pugh class B8 or C cirrhosis.
- •ECOG greater than or equal to
- •Uncontrolled ascites despite medical management.
- •Less than 800 cc of uninvolved liver.
- •Prior radiotherapy to the upper abdominal quadrant.
- •Prior antiangiogenic or tyrosine kinase inhibitor therapy Cardiac disease: Congestive heart failure > class II NYHA. Patients must not have unstable angina(anginal symptoms at rest) or new onset angina (began within the last 3 months) or myocardial infarction within the past 6 months.
- •Known brain metastasis. Patients with neurological symptoms must undergo a CT scan/MRI of the brain to exclude brain metastasis.
- •Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy.
- •Uncontrolled hypertension defined as systolic blood pressure > 150 mmHg or diastolic pressure >90 mmHg, despite optimal medical management.
- •Known human immunodeficiency virus (HIV) infection or chronic Hepatitis B or C.
- •Active clinically serious infection > CTCAE Grade
- •Thrombolic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past 6 months.
- •Pulmonary hemorrhage/bleeding event > CTCAE Grade 2 within 4 weeks of first dose of study drug.
- •Any other hemorrhage/bleeding event > CTCAE Grade 3 within 4 weeks of first dose of study drug.
- •Serious non-healing wound, ulcer, or bone fracture.
- •Evidence or history of bleeding diathesis or coagulopathy
- •Major surgery, open biopsy or significant traumatic injury within 4 weeks of first study drug.
- •Use of St. John's Wort or rifampin (rifampicin).
- •Known or suspected allergy to sorafenib or any agent given in the course of this trial.
- •Any condition that impairs patient's ability to swallow whole pills.
- •Any malabsorption problem.
- •Pregnant or lactating female.
Arms & Interventions
Radiation followed by Sorafenib
Experimental
Radiation therapy, stereotactic body radiation therapy followed by Sorafenib
Intervention: Sorafenib (Drug)
Radiation followed by Sorafenib
Experimental
Radiation therapy, stereotactic body radiation therapy followed by Sorafenib
Intervention: Stereotactic Body Radiotherapy (SBRT) (Radiation)
Outcomes
Primary Outcomes
Determine the Safety and Tolerability of Sequential SBRT and Sorafenib in Patients With Unresectable Hepatocellular Carcinoma
Time Frame: between baseline and 3 years
Number of subjects experiencing a Grade 5 toxicity related to SBRT and sorafenib
Secondary Outcomes
- The Degree of Change in Necrosis and Vascular Permeability Via Dynamic Contrast Enhanced (DCE) and Diffusion-weighted Imaging (DWI) Magnetic Resonance Imaging (MRI) as Measured by Tumor Volume(baseline, 4 weeks and 10 weeks)
- The Degree of Change in Necrosis and Vascular Permeability Via Dynamic Contrast Enhanced (DCE) and Diffusion-weighted Imaging (DWI) Magnetic Resonance Imaging (MRI) as Measured by Ktrans (Volume Transfer Coefficient).(baseline, 4 weeks and 10 weeks)
- The Degree of Change in Necrosis and Vascular Permeability Via Dynamic Contrast Enhanced (DCE) and Diffusion-weighted Imaging (DWI) Magnetic Resonance Imaging (MRI) as Measured by Kep. Kep Describes How Fast Contrast Can Redistribute in Tissue.(baseline, 4 weeks after baseline and 10 weeks post baseline)
- The Degree of Change in Necrosis and Vascular Permeability Via Dynamic Contrast Enhanced (DCE) and Diffusion-weighted Imaging (DWI) Magnetic Resonance Imaging (MRI) as Measured by ADC (Apparent Diffusion Coefficient).(baseline, 4 weeks post baseline, 10 weeks post baseline)
Investigators
Dr. Kimberly Keene
Assistant Professor
University of Alabama at Birmingham
Study Sites (1)
Loading locations...
Similar Trials
Active, not recruiting
Phase 2
SBRT Followed by Neoadjuvant Immunochemotherapy in Resectable Stage II to III Non-small Cell Lung CancerCarcinoma, Non-Small-Cell LungNCT05319574Sun Yat-sen University46
Unknown
Phase 2
SBRT Compared With IMRT Concurrently With Chemotherapy in Treating Patients With LS-SCLCSmall Cell Lung CancerNCT02738723Third Military Medical University50
Active, not recruiting
Not Applicable
Stereotactic Body Radiotherapy (SBRT) for Medically Inoperable Localised Renal Tumors (SABINA Trial)Kidney NeoplasmRenal CancerInoperable DiseaseSBRTSABRNCT05817604Consorci Sanitari de Terrassa60
Recruiting
Not Applicable
Systemic Anti-tumor Activity and Safety of the Combination of SBRT and Concurrent PD-1 Blockade in Metastatic RCC.NCT06327178Nanfang Hospital, Southern Medical University20
Withdrawn
Phase 2
A Study of SBRT in Combination With rhGM-CSF for Stage IV NSCLC Patients Who Failed in Second-line ChemotherapyCarcinoma, Non-Small-Cell LungNCT02623595Wuhan University